Retina

To speed care, Mount Sinai’s Department of Ophthalmology launched an Eye Stroke Service and developed a treatment protocol for patients.

David Hutton of Ophthalmology Times talks with Brian Strem, PhD, CEO Kiora Pharmaceuticals, about their recent partnership with Théa Open Innovation and further development of their KIO-301 and KOI-104 programs.

According to the organization, GYROS results will help researchers design clinical trials for an emerging gyrate atrophy gene therapy.

Researchers noted a study by Ruhr-University Bochum researchers provides crucial evidence that the ECM influences visual sensory motor behavior already at the retina level, without intervention of disease and/or experimental manipulation.

According to the company, AGTC-501 was generally safe and well-tolerated and showed improvements in visual function at the 12-month analysis. The Phase 2/3 VISTA trial for AGTC-501 in XLRP expected to begin in in the first half of 2024.

A team of neuroscientists at Johns Hopkins show how specialized cells signal the presence of light simultaneously in two distinct ways.

Toku’s AI technology, CLAiR, has obtained CE and UKCA Marks. CLAiR provides fast, accurate, non-invasive cardiovascular disease (CVD) risk assessments using standard retinal images.

Elodie Bousquet, MD, PhD, and international researchers studied type 3 macular neovascularization (T3 MNV) using optical coherence tomography. In 64.5% of 31 eyes with T3 MNV, it developed over soft drusen, showing drusen growth and outer layer thinning before T3 MNV.

Jennifer I. Lim, MD, FARVO, FASRS sat down with Hattie Hayes of Ophthalmology Times Europe to discuss her findings, including exciting advancements in targeting Ang2 and VEGF from the Angiogenesis Exudation and Degeneration 2024 event.

Anat Loewenstein, MD, sat down with Hattie Hayes of Ophthalmology Times Europe to discuss the implication of longitudinal AI-based fluid quantification for at-home monitoring from the Angiogenesis Exudation and Degeneration 2024 event.

Carl Danzig, MD, sat down with Martin David Harp of Ophthalmology Times to discuss his presentation AVD-104 for Geographic Atrophy: Glyco-immunologic modulation of macrophage activity from the Angiogenesis Exudation and Degeneration 2024 event.

According to the company, the deals from two global Phase III RVO studies will be presented at Angiogenesis, Exudation, and Degeneration 2024.

A University of Houston professor found that the excitement over the results of LLR as a treatment option for patients with myopia may have come too soon, before its efficacy was confirmed. One company is taking exception with the study.

Sanders is affiliated with the Retina Group of Washington (RGW) and PRISM Vision Group. He is the first African American and the first PRISM-affiliated physician to serve as president of the ASRS.

Researchers at Mass Eye and Ear have demonstrated that retinal imaging can help predict a person’s risk of developing ocular, neuropsychiatric, cardiac, metabolic, and pulmonary diseases.

LambdaVision is leveraging the microgravity environment of the space station to develop higher-quality implants than is currently possible on Earth.

ACDN-01 is the first-ever RNA exon editor to enter clinical development and the only clinical-stage therapeutic targeting the genetic cause of Stargardt disease. Ascidian expects to initiate enrollment in Phase 1/2 STELLAR study in the first half of 2024.

While the potential for fundus images is recognized, the methodology and clinical application must be improved.

According to the company, favorable safety and tolerability profiles were observed with the first 2 SPVN06 doses across 6 patients. The exploration of SPVN06 in geographic geographic atrophy is set to begin in 2024.

Genetic testing is proving to be an evolving technology for ophthalmologists.

Two retina specialists participated in an Ophthalmology Times case-based roundtable discussion and shared their experiences using the anti-VEGF biosimilars, ranibizumab-eqrn and ranibizumab-nuna to manage retinal diseases.

David Eichenbaum, MD, discussed the status of the technology at the Retina 2024 meeting in Maui.

Varun Chaudhary, MD, FRCSC, addressed the big questions in treating patients with retinal vascular diseases at the Retina 2024 meeting in Maui.

According to the company, all three patients treated for two years or more have remained free of symptoms and disease progression while taking gildeuretinol.

The Retina Program 2024 will convene during the Hawaiian Eye meeting in Maui from January 14 through January 19

Hawaiian Eye and Retina 2024 meetings will take place from January 13 to 19 at the Grand Wailea Maui, 3850 Wailea Alanui Drive, Wailea, HI.

According to researchers, the strongest biomarker was achieved from a single bright flash of light to the right eye, with AI processing significantly reducing the test time.

Catch up on a few of Modern Retina's top stories and ones you may have missed in 2023

A genome topology map of human retina development lays the foundation for understanding diverse clinical phenotypes in simple and complex eye diseases.

Scientists have developed a versatile imaging system that will help diagnose pathologies in the eye fundus.